News

Nov 03, 2024

Beijing Chunlizhengda Medical Instruments Third Quarter 2024 Earnings: CN¥0.045 loss per share (vs CN¥0.14 profit in 3Q 2023) - Simply Wall St News

All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 22% growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong.

Performance of the Hong Kong Medical Equipment industry.

The company's shares are down 2.9% from a week ago.

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Beijing Chunlizhengda Medical Instruments' balance sheet health.

Discover if Beijing Chunlizhengda Medical Instruments might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

An orthopedic medical device company, engages in the research and development, production, and trading of surgical implants, instruments, and related products in the People’s Republic of China.

High growth potential with excellent balance sheet.